Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxart, Inc. (VXRT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain the contents of each document in clear language. As a clinical-stage biotechnology company developing oral recombinant pill vaccines, Vaxart uses its filings to report on clinical progress, collaborations, listing status and material agreements that shape its vaccine platform and financial position.
Through Vaxart’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, investors can review detailed discussions of its oral vaccine programs for coronavirus, norovirus, influenza and HPV, as well as information on research and development spending, government contract revenue and risk factors. Current reports on Form 8‑K highlight specific events, such as the exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s oral COVID-19 vaccine candidate, updates on the BARDA-funded Project NextGen Phase 2b trial, lease terminations related to cost reduction efforts, and governance and listing developments.
For trading status, Vaxart’s 8‑K filings and the Form 25 filed by Nasdaq Stock Market LLC document the suspension and removal of the company’s common stock from Nasdaq and its quotation on the OTCQX Best Market under the symbol VXRT. These filings provide the official record of Vaxart’s transition from a national exchange to OTCQX and the conditions that led to delisting.
On this page, users can also monitor any registration statements, prospectus supplements and other capital markets filings that Vaxart uses to raise funds or register securities, as well as any future proxy materials related to corporate actions. Stock Titan’s AI tools summarize long forms such as 10‑K and 10‑Q, highlight key sections on clinical programs, government contracts and collaboration terms, and surface important items from 8‑Ks so that readers can quickly understand how each filing may relate to Vaxart’s oral vaccine development and trading status.
Vaxart, Inc. reported an insider equity transaction by SVP and General Counsel Edward B. Berg related to tax withholding on vested stock awards. On March 18, 2026, 8,072 shares of common stock were disposed of at $0.6346 per share to satisfy income tax withholding obligations in connection with the net settlement of RSUs that vested on that date. This was not an open-market sale but a routine, issuer-withheld share disposition for taxes. Following the transaction, Berg directly held 791,786 common shares, which includes 70,781 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported a routine share withholding tied to restricted stock units. On March 18, 2026, 6,772 shares of common stock were withheld at $0.6346 per share to cover income tax obligations for vested RSUs. After this tax-withholding disposition, he directly holds 958,020 shares of Vaxart common stock, which includes 75,618 shares acquired under the 2022 Employee Stock Purchase Plan.
Vaxart, Inc. President and CEO Steven Lo reported a tax-related share disposition tied to RSU vesting. On March 18, 2026, 22,425 shares of common stock were withheld by the company at $0.6346 per share to cover income tax obligations on vested RSUs, a non-market transaction coded as "F." After this withholding, Lo directly owned 2,611,634 common shares and indirectly held 100,000 additional shares through the Lo Family Trust, indicating that his overall equity stake remains substantial despite the routine tax withholding.
Vaxart, Inc. senior executive Sean Tucker reported a routine tax-related share disposition tied to restricted stock unit vesting. On March 18, 2026, 8,072 shares of common stock were withheld by the company to cover income tax obligations from RSUs that vested on that date, a non-market transaction rather than an open-market sale. After this withholding, Tucker directly holds 923,153 common shares and has additional indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse.
Vaxart, Inc. director and CEO Steven Lo received new equity awards as part of his compensation. He was granted stock options for 1,543,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. These options vest 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030.
Lo also received a grant of 846,500 shares of common stock upon vesting of restricted stock units. Those units vest 25% on each anniversary of the vesting commencement date of March 16, 2026, fully vesting on the fourth anniversary. Following these awards, he directly holds 2,634,059 common shares and 1,543,000 options, plus an indirect holding of 100,000 shares through the Lo Family Trust.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported equity awards rather than open-market trades. He received a stock option covering 410,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030.
He also acquired 200,000 shares of common stock at no cash cost in connection with restricted stock units, which are scheduled to vest 25% on each anniversary of the March 16, 2026 vesting commencement date until the fourth anniversary. Following these awards, he directly holds 931,225 common shares, with additional indirect holdings of 51,465 shares in joint tenancy and 9,060 shares held by his spouse.
Vaxart, Inc.’s Chief Financial Officer, Jeroen Nicolaas Grasman, reported equity compensation grants. He was awarded 227,000 shares of Common Stock upon vesting of restricted stock units, bringing his direct Common Stock holdings to 577,000 shares.
He also received a stock option covering 455,000 shares of Common Stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The restricted stock units vest 25% on March 16, 2026 and then annually so they are fully vested on the fourth anniversary, while the option vests 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030. These are compensation-related awards rather than open-market purchases.
Vaxart, Inc. reported that Chief Medical Officer James F. Cummings received new equity awards on March 16, 2026. He was granted stock options for 455,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030. He also received 227,000 shares of common stock through vesting of restricted stock units, which vest 25% on each anniversary of March 16, 2026 over four years. Following these grants, he holds 964,792 shares of common stock directly.
Vaxart, Inc. SVP and General Counsel Edward B. Berg received new equity awards as part of his compensation. On March 16, 2026, he was granted 115,000 shares of common stock upon vesting of restricted stock units, with 25% of the units vesting on each anniversary of the March 16, 2026 vesting commencement date until fully vested after four years.
He was also granted a stock option for 225,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments so it is fully vested by March 16, 2030. Following these grants, Berg directly holds 799,858 common shares.
Vaxart, Inc. files its Annual Report describing progress on its oral tablet vaccine pipeline and regulatory environment. The company focuses on norovirus, COVID-19, influenza and HPV using its VAAST oral adenovirus-based platform to induce mucosal and systemic immunity via enteric‑coated tablets.
Vaxart reports positive Phase 1 data for a second‑generation bivalent norovirus vaccine showing large increases in functional antibodies and fecal IgA, and outlines plans to advance development with additional funding or partners. It also details a large BARDA‑funded Phase 2b COVID‑19 booster study using an oral KP.2‑targeted candidate versus an approved mRNA comparator, where about 5,400 adults were enrolled before U.S. authorities halted further enrollment but allowed 12‑month follow‑up to continue under a contract currently funded up to $316.0 million.
The filing further reviews prior BARDA‑funded influenza challenge data, an early HPV therapeutic vaccine program, in‑house and outsourced GMP manufacturing capabilities, extensive U.S. and foreign regulatory requirements, and a competitive landscape where no vaccines yet exist for norovirus or HPV therapy. As of June 30, 2025, non‑affiliate market value of common stock was $102,712,906 at $0.45 per share, and 240,634,372 shares were outstanding as of March 6, 2026.